Somite Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Somite Therapeutics, Inc. - overview
Established
2023
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2023, Somite Therapeutics, Inc. operates as a biotechnology research company that uses AI to produce human tissue for cell therapies, ultimately aiming to cure various diseases by addressing cell population deficiencies. The company was co-founded by Micha Breakstone (CEO), Allon Klein, and Cliff Tabin. In May 2025, Somite Therapeutics, Inc.
raised USD 47. 5 million in series A funding led by new investor Khosla Ventures, with participation from other new investors SciFi VC, Chan Zuckerberg Initiative, Fusion Fund, Ajinomoto, Pitango HealthTech, TechAviv and Harpoon Ventures. Individual investors also participated in the round. The company's AlphaStem platform focuses on developing AI foundation models to create human tissue at scale for diseases like diabetes, obesity, and muscular dystrophies.
Somite's innovative approach involves building digital twins of the embryo, which are computational models mirroring real embryonic development, to guide cell differentiation protocols and optimize production variability in cell replacement therapies. The company will use the May 2025 funding for further development of DeltaStem.
Current Investors
Lerer Hippeau Ventures, Texas Ventures, Next Coast Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.somite.ai
Verticals
Artificial Intelligence
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.